Navigation Links
Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18
Date:3/17/2008

BALTIMORE, March 17 /PRNewswire-USNewswire/ -- The following was issued today by the Greater Baltimore Committee:

WHO:

Donald C. Fry, president & CEO, Greater Baltimore Committee

140 company owners, executives and researchers from the Baltimore-area bioscience community

WHAT:

The third annual Greater Baltimore Region Bioscience Awards

WHEN:

Tuesday, March 18, 2008

8:00 a.m. / Breakfast & Registration

8:45 - 9:30 a.m. / Awards Program

WHERE:

Renaissance Harborplace Hotel, 202 East Pratt Street, Baltimore, MD 21202

DETAILS:

More than 140 leaders from the Baltimore region's bioscience industry and research community will attend a breakfast reception at the Greater Baltimore Committee to honor winners of the 2008 Greater Baltimore Region Bioscience Awards.

This is the third annual awards event presented by the Greater Baltimore Committee, the region's most prominent organization of business and civic leaders, to recognize outstanding achievements in the region's bioscience industry. The Greater Baltimore Committee has made support for the emerging bioscience industry in the region one of its top long-term priorities.

Award winners, to be announced, were selected from among 22 nominations submitted by businesses, bioscience advocates, higher education institutions and government officials.

Awards will be presented in the following categories: Best New Product or Progress Award, Entrepreneurship Award, Leadership in Bioscience Award, and President's Award.

Nominees for this year's awards are:

Best New Product or Progress Award

-- Kris Appel, President & CEO, Encore Path, Inc.

-- Timothy E. Askew, President & CEO, CSA Medical, Inc.

-- James Campbell, M.D., CEO, Arcion Therapeutics

-- William G. Hearl, Ph.D., Founder & President, Immunomic Therapeutics, Inc.

-- Ryan Sysko, Founder & CEO, WellDoc Communications, Inc.

Entrepreneurship Award

-- Mohamed S. Al-Ibrahim, MB ChB, FACP, COO & President, SNBL Clinical Pharmacology Center, Inc.

-- Scott Allocco, President, BioMarker Strategies, LLC

-- Atul Bedi, M.D., Founder, President & Chief Executive Officer, IATRICa Inc.

-- David S. Block, Founder & CEO, Gliknik, Inc.

-- Julie D. Suman, R.Ph., Ph.D., Co-founder & President, Next Breath, LLC

-- Reza Mazhari, Ph.D., VP, Research & Pharmacology and Peter Suzdak, Ph.D.,President/CEO & Co-founder, Cardioxyl Pharmaceuticals, Inc.

-- Jian Wang, Ph.D., President & CEO, BioFortis

Leadership in Bioscience Award

-- Drew M. Pardoll, M.D., Ph.D., Amplimmune

-- Blake M. Paterson, M.D., CEO and Co-founder, Alba Therapeutics Corporation

President's Award

-- Stephen P. Auvil, Co-PI, Director, Office of Technology Development, UMBC and the ACTiVATE Program

-- Delegate Dan K. Morhaim, M.D., The Maryland House of Delegates, 11th District, Baltimore County

-- David J. Ramsay, DM, DPhil, President, University of Maryland, Baltimore

-- John T. (Jack) Shannon, Jr., President and CEO, East Baltimore Development Inc. and Scott Levitan, Senior Vice President, Development Director, Forest City Science + Technology Group, Forest City - New East Baltimore Partnership

-- Paul Silber, Former President/CEO & Founder, InVitro Technologies, Inc.

-- Kathleen O'Donnell Weiss, Executive Director, The BioTechnical Institute of Maryland, Inc.

Program sponsor for the event is KAWG&F. Media sponsor is The Daily Record.

To attend and cover this event, contact: Diane Hughes, 410-727-2820, x32


'/>"/>
SOURCE Greater Baltimore Committee
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
2. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
3. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
4. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
5. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
6. California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says
7. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
8. California IVF Experts Tap Ethics Committee for Guidance
9. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
10. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
11. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... , May 19, 2016 There ... fully recover given the relentless pressures in pricing and ... in the investors circle though - numerous opportunities are ... of today,s session, ActiveWallSt.com,s presents four names in this ... Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera ...
(Date:5/18/2016)... Irvine, Calif. (PRWEB) , ... May 18, 2016 , ... ... had awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit ... innovative company that is financed by one of ACA’s member angel groups. It is ...
(Date:5/18/2016)... Washington, PA (PRWEB) , ... May 18, 2016 ... ... at least 1,200 hospitalizations are a direct result of asthma complications.* Costing more ... challenge across the country. , “For too many, the suffering ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):